Grimaldi, D. http://orcid.org/0000-0001-8428-065X
Legriel, S.
Pichon, N.
Colardelle, P.
Leblanc, S.
Canouï-Poitrine, F.
Ben Hadj Salem, O.
Muller, G.
de Prost, N.
Herrmann, S.
Marque, S.
Baron, A.
Sauneuf, B.
Messika, J.
Dior, M.
Creteur, J.
Bedos, J. P.
Boutin, E.
Cariou, A.
Funding for this research was provided by:
DRCI Versailles
Article History
Received: 29 November 2021
Accepted: 2 March 2022
First Online: 14 March 2022
Change Date: 27 March 2022
Change Type: Update
Change Details: The Family Name, Given Name were interchanged for the author O. Ben Hadj Salem in the original publication, this article has been updated.
Declarations
:
: Approval was obtained from an independent ethics committee in both countries (Comité de Protection des Personnes CPP Ile de France XI, #14059 and Ethic Committee Erasme Hospital P2016/319). The trial complied with the Declaration of Helsinki, Good Clinical Practices, and French regulatory requirements. Patients were unable to provide informed consent at inclusion. Written informed consent was therefore obtained from their next-of-kin or surrogate; a written informed consent was obtained from the patients when they regained consciousness, in compliance with French and Belgian laws.
: Not applicable.
: JM received congress reimbursement fees from CSL Behring & Biotest. DG received consultation fees from Transgene SA Illkirch Graffenstaden (France). AC received fees from Bard for lectures. Other authors have no disclosures.